LNSR

BEARISH

$5.7 Live

LENSAR, Inc. · NASDAQ

Target $8.5 (+49.1%)

$5.33 52W Range $14.31

LNSR LENSAR, Inc. - Fundamental Analysis

BEARISH

Console Chart News

LNSR Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Devices

Current Price Live

$5.7

Analyst Target

$8.5

+49.1% Upside

52W High

$14.31

52W Low

$5.33

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 13, 2026

Market cap

$68.95M

P/E

N/A

ROE

-1069.4%

Profit margin

-58.7%

Debt/Equity

N/A

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

95%

LNSR exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.63, indicating negative shareholder equity. The company is suffering from catastrophic profitability metrics, including an ROE of -1069.41% and an operating margin of -116.03%. Despite a 'strong_buy' analyst consensus from a very small sample (2 analysts), the fundamental data shows declining revenue (-4.20% YoY) and a consistent failure to meet earnings estimates (0/4 beats in the last year). The technical trend is aggressively bearish, with a 51.6% price collapse in the last month alone.

Key Strengths

Positive gross margin of 46.41%

Relatively low Price-to-Sales ratio of 1.18

Current ratio of 1.15 provides a marginal liquidity cushion

Analyst target price ($8.50) suggests potential upside if a turnaround occurs

Operates in the high-value Medical Devices industry

Key Risks

Negative equity (P/B -2.63) indicating insolvency risk

Severe operational inefficiency with -116.03% operating margin

Negative revenue growth (-4.20% YoY) suggesting loss of market share

Extreme price volatility and strong downward momentum (-57.5% 1Y change)

Consistent earnings misses with an average surprise of -26.12% over the last 4 quarters

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk / Distressed

Key drivers: Negative Equity, Piotroski F-Score 1/9, Negative Revenue Growth, Catastrophic ROE

Confidence

90%

Value

10/100

P/B of -2.63 indicates the company's liabilities exceed its assets.

Positives

Low P/S ratio

Watchpoints

Negative P/B ratio
No Graham Number due to negative earnings

Future

15/100

Revenue growth is -4.20% and EPS growth is -100%.

Positives

Analyst target price above current market price

Watchpoints

Negative YoY revenue growth
Negative EPS growth
Consistent earnings misses

Past

20/100

Recent performance shows a rapid collapse from 52-week highs of $14.31.

Positives

3Y change was positive (+119.2%)

Watchpoints

1Y change -57.5%
1M change -51.6%

Health

5/100

F-Score of 1/9 is a strong deterministic signal of financial weakness.

Positives

Current ratio > 1.0

Watchpoints

Piotroski F-Score 1/9
Quick ratio 0.60
Negative equity

Dividend

0/100

Dividend strength is 0/100.

Positives

No standout positives identified.

Watchpoints

No dividend paid
No dividend history

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$5.7

Analyst Target

$8.5

Upside/Downside

+49.1%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for LNSR and closest competitors.

Updated 2026-04-10

Company	5Y	3Y	1Y	6M	1M	1W
LNSR LENSAR, Inc. Primary	-17.5%	+119.2%	-57.5%	-52.1%	-51.6%	-5.9%
FORA Forian Inc. Peer	-82.8%	-35.5%	+13.5%	-7.0%	+2.9%	+1.9%
HCAT Health Catalyst, Inc. Peer	-98.0%	-92.3%	-74.0%	-62.4%	-46.4%	-14.8%
ATHE Alterity Therapeutics Limited Peer	-80.8%	-8.5%	+6.3%	-45.8%	+14.5%	+2.9%
ICCC ImmuCell Corporation Peer	-21.2%	+44.8%	+39.6%	+4.1%	+6.5%	+9.9%

LNS

LENSAR, Inc.

Primary

-17.5%

+119.2%

-57.5%

-52.1%

-51.6%

-5.9%

FOR

Forian Inc.

Peer

-82.8%

-35.5%

+13.5%

-7.0%

+2.9%

+1.9%

HCA

Health Catalyst, Inc.

Peer

-98.0%

-92.3%

-74.0%

-62.4%

-46.4%

-14.8%

ATH

Alterity Therapeutics Limited

Peer

-80.8%

-8.5%

+6.3%

-45.8%

+14.5%

+2.9%

ICC

ImmuCell Corporation

Peer

-21.2%

+44.8%

+39.6%

+4.1%

+6.5%

+9.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-8.03

N/A

-2.63

1.18

1.16

-3.36

$68.95M

Profitability

Profit margins and return metrics

Profit Margin -58.66%

Operating Margin -116.03%

Gross Margin 46.41%

ROE -1069.41%

ROA -22.31%

Growth

Revenue and earnings growth rates

Revenue Growth -4.2%

Earnings Growth N/A

Q/Q Revenue Growth -4.22%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

N/A

Current Ratio

1.15

Good

Quick Ratio

0.6

Poor

Cash/Share

$1.49

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

43.3%

Op. Margin

-30.7%

Net Margin

-9.1%

Total Assets

$0.1B

Liabilities

$0.1B

Equity

$-0.0B

Debt/Equity

-3.75x

Operating CF

$0.0B

Free Cash Flow

$0.0B

FCF Yield

100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07

$N/A

2026-03-31

$-0.12

-33.3% surprise

2026-03-31

$-0.11

-7.8% surprise

2025-11-06

$-0.11

-37.2% surprise

Healthcare Sector Comparison

Comparing LNSR against 291 companies in the Healthcare sector (20 bullish, 99 neutral, 172 bearish)

Return on Equity (ROE)

-1069.41%

This Stock

-49.88%

Sector Avg

+2044.1% (Excellent)

Profit Margin

-58.66%

This Stock

-9.43%

Sector Avg

+521.8% (Superior)

Revenue Growth

-4.2%

This Stock

80.78%

Sector Avg

-105.2% (Slower)

Current Ratio

1.15

This Stock

3.72

Sector Avg

-69.0% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
LNSR LENSAR, Inc.	BEARISH	$68.95M	-	-1069.4%	-58.7%	$5.7
FORA Forian Inc.	BEARISH	$66.86M	-	-9.6%	-9.5%	$2.14	Compare
HCAT Health Catalyst, Inc.	BEARISH	$73.31M	-	-58.3%	-57.2%	$1.0	Compare
ATHE Alterity Therapeutics Limited	BEARISH	$64.35M	-	-43.2%	-223.3%	$3.55	Compare
ICCC ImmuCell Corporation	BEARISH	$64.01M	-	-3.8%	-3.8%	$7.08	Compare

LNSR LENSAR, Inc.

BEARISH

Mkt Cap

$69M

P/E

ROE

-1069.4%

Price

$5.7

Compare with LNSR

HCAT Health Catalyst, Inc.

Compare with LNSR

Compare with LNSR

ICCC ImmuCell Corporation

Compare with LNSR

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-03-19	STAAB THOMAS R II	Chief Financial Officer	Option Exercise	5,500	$14,575

STAAB THOMAS R II

Chief Financial Officer

Option Exercise

2026-03-19

5,500 shares · $14,575

Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

STRONG_BUY

2 analysts

BTIG

2026-03-18

Neutral Buy

Past News Coverage

Recent headlines mentioning LNSR from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

LNSR

LNSR LENSAR, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!